anti-CEA CAR T-cell therapy (HuaDao (Shanghai) Biomedical)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-CEA CAR T-cell therapy (HuaDao (Shanghai) Biomedical)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulatorsT lymphocytes stimulantsImmunostimulants
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsLiver NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Rui Jin Hospital
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSuzhou Huadao Biological Pharmaceutical Co LtdShanghai Rui Jin Hospital
Active IndicationsN/A
Inactive IndicationsLiver NeoplasmsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A